AstraZeneca will hold a clinic in India on its “promising” Covid-19 vaccine candidate in progress with the University of Oxford.
“Let’s take an exam in India. It’s a big country and there are a lot of infections,” Pascal Soriot, CEO of AstraZeneca, told BusinessLine, an interaction with the media after the media media’s middle knowledge of the possible vaccine showed positive effects in terms of strong responses to antibodies and T cells.
Detailing the ongoing Phase I/II COV001 trial, led by the University of Oxford, the company stated that the interim effects showed that “AZD1222 tolerated and generated physically powerful immune responses opposed to SARS-CoV-2 in all participants evaluated”.
“We’re on the right track,” Soriot said on the September schedule to be able to get the vaccine, however, it could take a few more months, he said, as trials depended on the infection rate of others with the virus. in the country. Region.
The only way to be in one position is to manufacture in parallel with the clinical trial, he said, about the “at risk” production that AstraZeneca had undertaken to supply UK and other governments from the beginning.
AstraZeneca has several distribution links, adding one with the Serum Institute in Pune for one billion doses in low- and middle-income countries.
Serum’s executive leader, Adar Poonawalla, said in a statement: “We will seek approval from the Indian regulator within a week. As soon as we get permission, we’ll start testing the vaccine in India. In addition, we will soon begin production of the vaccine in gigantic quantities ».
The head of AstraZeneca said the company is advancing with Phase II/III Phase II/III clinical trials in the UK, Brazil, South Africa and the US, in all likelihood until the end of the month, he said. So, at the end of all the trials, there would be a giant database on vaccine safety, he said.
COV001 is a randomized, multicenter and blind phase I/II controlled trial with 1,077 healthy, elderly adult participants aged 18 to 55 years. It evaluated a single dose of AZD1222 compared to a meningococcal conjugate vaccine, MenACWY. Ten participants also won two doses of AZD1222 within a month of another, AZ said.
Results published in The Lancet showed that a single dose of AZD1222 resulted in a quadruple accumulation of antibodies targeted against the complex SARS-CoV-2 protein in 95% of participants one month after injection. In all participants, a T-cell reaction was induced, peaking on day 14 and remaining two months after the injection, the note added.
Professor Andrew Pollard, Chief investigator of the Oxford Vaccine Trial at Oxford University and co-author of the trial, said: “The interim Phase I/II data for our coronavirus vaccine shows that the vaccine did not lead to any unexpected reactions and had a similar safety profile to previous vaccines of this type. The immune responses observed following vaccination are in line with what we expect will be associated with protection against the SARS-CoV-2 virus, although we must continue with our rigorous clinical trial programme to confirm this. We saw the strongest immune response in participants who received two doses of the vaccine, indicating that this might be a good strategy for vaccination.”
Existing users, log in here
Access Hindu Businessline content on desktops, tablets, and mobile devices.
Get diverse set of perspectives from our trusted experts on Portfolio, Banking, Economy, Environment and others.
Discover an ad-free cleaner and faster charging times.
Customize your personal tastes and get personalized story advice about your interest.
Existing users, please Sign in here
More